The UK’s Medical Research Council is funding a 10-patient Phase I study to deliver rapid personalised treatment for lung cancer patients.

As of March 2024, the FDA has approved three CD20 × CD3 BsAbs: mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma (R/R FL), glofitamab (Columvi) for relapsed or refractory diffuse B cell lymphoma

Sino Biological and Rapid Novor partner to offer combined antibody development and sequencing services.

InSphero's Liver Disease team has published a groundbreaking peer-reviewed paper in Nature's Scientific Reports, challenging the limitations of in vitro models in MASH Drug Discovery.

ProBioGen, is pleased to announce the execution of services and license agreements with MAPP BIOPHARMACEUTICAL, INC. to develop a cell line for an afucosylated antibody targeting Marburg virus (MARV) infection.

The Noramco group addresses critical supply chain challenges, offering comprehensive active pharmaceutical ingredients (API) and drug product solutions.

New data builds on earlier findings from a post-hoc Phase 2 analysis that helped reposition BioSenic’s oral arsenic trioxide (OATO) program for pivotal trials.

Growth of suppository manufacturing capabilities addresses increasing market demand to meet the needs
of geriatric and pediatric patients, and women’s health.

Exceptional capabilities in guiding therapies from early-stage development through to market based on over 50 years of biotech experience.

AMSBIO has expanded its range of products and services dedicated to assisting scientists diversify their preclinical models effectively to help bridge the gender discrepancy gap in many areas of research.